Clinical Trial Update: A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety [Phase 3]

View source ↗

Summary

Pfizer reports termination of a long-term Phase 3 study evaluating CP-945,598 for weight loss and safety in obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-945,598 (CP-945,598)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 3 | Status: TERMINATED